Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder

Dyskinesias are known to occur in many patients with Parkinson's disease treated with dopaminergic drugs but to date, drug‐induced dyskinesias have not been observed in humans with no underlying basal ganglia disorder. We describe a patient with psychogenic parkinsonism and intravenous apomorphine abuse leading to subsequent choreatiform dyskinesias. © 2004 Movement Disorder Society

[1]  J. Cummings.  A window on the role of dopamine in addiction disorders. , 2000, Journal of neurology, neurosurgery, and psychiatry.

[2]  M. Okun,et al.  Rationale for current therapies in Parkinson’s disease , 2003, Expert opinion on pharmacotherapy.

[3]  Erwan Bezard,et al.  Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.

[4]  Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, The New England journal of medicine.

[5]  E. Tolosa,et al.  DAT imaging in drug‐induced and psychogenic parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.

[6]  Jae-Hong Lee,et al.  Isolated tongue tremor after gamma knife radiosurgery for acoustic schwannoma , 2005, Movement disorders : official journal of the Movement Disorder Society.

[7]  H. Klawans.  Levodopa-Induced Psychosis , 1978 .

[8]  P. Jenner.  Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments , 2000, Journal of Neurology.

[9]  M. Sabbagh,et al.  Pseudoneurologic syndromes: recognition and diagnosis. , 1998, American family physician.

[10]  P. Jenner,et al.  L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations , 2001, Psychopharmacology.

[11]  J. Sanchez-Ramos,et al.  Visual hallucinations associated with Parkinson disease. , 1996, Archives of neurology.

[12]  S. Leurgans,et al.  Prospective longitudinal assessment of hallucinations in Parkinson’s disease , 2001, Neurology.

[13]  G. Stebbins,et al.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease , 1995, Neurology.

[14]  J. Friedman,et al.  The Role of Atypical Antipsychotics in the Treatment of Movement Disorders , 1999 .

[15]  A Schrag,et al.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. , 2000, Brain : a journal of neurology.

[16]  S. Factor,et al.  Psychogenic movement disorders: frequency, clinical profile, and characteristics. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[17]  P J Feustel,et al.  Longitudinal outcome of Parkinson’s disease patients with psychosis , 2003, Neurology.

[18]  J. Lieberman,et al.  Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. , 1993, The New England journal of medicine.

[19]  H. Fernandez.  Quetiapine for l-dopa–induced psychosis in PD , 2000, Neurology.

[20]  O. Spigset,et al.  Levodopa Dependence and Abuse in Parkinson's Disease , 1997, Pharmacotherapy.

[21]  S. Kulkarni,et al.  Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. , 2003, Drugs of today.

[22]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[23]  S. Factor,et al.  A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. , 2001, Archives of neurology.

[24]  J. Cummings,et al.  Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[25]  P. Jenner.  The MPTP-treated primate as a model of motor complications in PD , 2003, Neurology.

[26]  A. Lees,et al.  Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies , 2000, Journal of neurology, neurosurgery, and psychiatry.